CN106456644B - 雄激素合成调节剂 - Google Patents

雄激素合成调节剂 Download PDF

Info

Publication number
CN106456644B
CN106456644B CN201580024124.6A CN201580024124A CN106456644B CN 106456644 B CN106456644 B CN 106456644B CN 201580024124 A CN201580024124 A CN 201580024124A CN 106456644 B CN106456644 B CN 106456644B
Authority
CN
China
Prior art keywords
day
acid
disclosed
conjugated
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580024124.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456644A (zh
Inventor
苏珊妮·简·迪利
格雷戈里·艾伦·斯托洛弗
保罗·克里斯多佛·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tangent Reprofiling Ltd
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of CN106456644A publication Critical patent/CN106456644A/zh
Application granted granted Critical
Publication of CN106456644B publication Critical patent/CN106456644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580024124.6A 2014-05-09 2015-05-11 雄激素合成调节剂 Active CN106456644B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990800P 2014-05-09 2014-05-09
US61/990,800 2014-05-09
PCT/EP2015/060388 WO2015169971A1 (en) 2014-05-09 2015-05-11 Modulators of androgen synthesis

Publications (2)

Publication Number Publication Date
CN106456644A CN106456644A (zh) 2017-02-22
CN106456644B true CN106456644B (zh) 2021-06-15

Family

ID=53269444

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580024124.6A Active CN106456644B (zh) 2014-05-09 2015-05-11 雄激素合成调节剂

Country Status (8)

Country Link
EP (1) EP3139923B1 (cg-RX-API-DMAC7.html)
JP (1) JP6730194B2 (cg-RX-API-DMAC7.html)
CN (1) CN106456644B (cg-RX-API-DMAC7.html)
AU (3) AU2015257594A1 (cg-RX-API-DMAC7.html)
CA (1) CA2950800C (cg-RX-API-DMAC7.html)
ES (1) ES2970762T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ726050A (cg-RX-API-DMAC7.html)
WO (1) WO2015169971A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
MA56457A (fr) 2019-07-02 2022-05-11 Regeneron Pharma Modulateurs de hsd17b13 et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319950B1 (en) * 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
WO2014049071A1 (en) * 2012-09-26 2014-04-03 Tangent Reprofiling Limited Modulators of androgen synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2436536C (en) * 2000-12-23 2008-07-08 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
WO2012129673A1 (en) * 2011-03-25 2012-10-04 Universite Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
US9375433B2 (en) * 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319950B1 (en) * 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
WO2014049071A1 (en) * 2012-09-26 2014-04-03 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
AU2015257594A1 (en) 2016-11-24
NZ726050A (en) 2018-04-27
CA2950800C (en) 2023-01-10
AU2018203135A1 (en) 2018-05-24
ES2970762T3 (es) 2024-05-30
WO2015169971A1 (en) 2015-11-12
EP3139923A1 (en) 2017-03-15
AU2019279922A1 (en) 2020-01-16
CA2950800A1 (en) 2015-11-12
JP6730194B2 (ja) 2020-07-29
EP3139923B1 (en) 2023-09-27
CN106456644A (zh) 2017-02-22
JP2017514816A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
US10111877B2 (en) Modulators of androgen synthesis
JP6734346B2 (ja) アンドロゲン合成モジュレーター
EP3139923B1 (en) Composition for treating pancreatic adenocarcinoma
JP5525447B2 (ja) Parp阻害剤としてのキノリノン誘導体
JP2017514816A5 (cg-RX-API-DMAC7.html)
KR20230084163A (ko) 항체-약물 접합체와 parp1 선택적 억제제의 조합
WO2022261643A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
Gras Niraparib hidrochloride
HK1240924B (en) A deuterated triazolopyridazine as a kinase modulator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant